MIL.BO · BSE
Medico Intercontinental Limite
₹24.37
+3.26% (+₹0.77)
Prev. close
₹23.6
Volume
1,557
As of
25 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Medico Intercontinental Limite
Medico Intercontinental Limited engages in the trading of pharmaceutical products. It offers products in the gastro, uro, nutrition, cosmetology, and other areas, as well as provides health devices and hospital related products. The company also provides general and derma range products in various forms, such as tablets, soft gelatine, capsules, dental, ointments, powders and sprays, liquids, ayurvedics, injectables, dry syrup, suspension, drops, infusion, soap, and nutritional; and medical FTF products, including antiseptic liquid, multipurpose cleaner, hand wash, immunity booster, and N95 face mask products, liquid, gel, and spray hand sanitizer, as well as eye drops. The company was formerly known as Intercontinental Leasing & Finance Company Limited and changed its name to Medico Intercontinental Limited in December 2018. Medico Intercontinental Limited was incorporated in 1984 and is based in Ahmedabad, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Dilipkumar Bhogilal Shah
Headquarters
Ahmedabad
Employees
41
Website
medicointercontinental.comExchange
View on BSE ↗Key stats
Market cap
₹24.37 Cr
EPS (TTM)
₹-3.97
Beta (1Y · daily vs NIFTY 50)
0.48
Beta (5Y · monthly vs NIFTY 50)
0.43
Shares float
36.79 L
EPS · quarter ended Jun 2026
₹-1.45
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: Yahoo (no NSE corporate-actions ledger for this listing).
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹69.74 Cr | ₹74.26 Cr | ₹76.23 Cr | ₹71.36 Cr | ₹95.32 Cr | ₹84.08 Cr | |
| EBITDA | ₹4.95 Cr | ₹5.31 Cr | ₹5.76 Cr | ₹6.21 Cr | ₹8.57 Cr | ₹4.06 Cr |
| ₹2.58 Cr | ₹3.10 Cr | ₹3.61 Cr | ₹3.95 Cr | ₹5.06 Cr | ₹-3.20 Cr | |
| Diluted EPS | ₹7.93 | ₹9.54 | ₹5.61 | ₹3.95 | ₹5.06 | ₹-3.2 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹58.88 Cr | ₹56.04 Cr | ₹76.92 Cr | ₹117.26 Cr | |
| — | — | ₹4.72 Cr | ₹4.85 Cr | ₹16.92 Cr | ₹67.23 Cr | |
| Stockholders' equity | — | — | ₹41.19 Cr | ₹45.03 Cr | ₹50.09 Cr | ₹46.89 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹-10.10 Cr | ₹5.58 Cr | ₹-6.26 Cr | ₹17.08 Cr | |
| Investing cash flow | — | — | ₹-5.38 Cr | ₹-8.54 Cr | ₹-4.93 Cr | ₹2.20 Cr |
| — | — | ₹20.41 Cr | ₹-45.79 L | ₹10.07 Cr | ₹-15.56 Cr | |
| Capital expenditure | — | — | ₹-42.18 L | ₹-1.23 Cr | ₹-1.93 Cr | ₹-4.64 Cr |
| End cash position | — | — | ₹6.79 Cr | ₹3.37 Cr | ₹2.24 Cr | ₹5.96 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.44 L Cr | ₹1,852.2 | 37.0 | 5.31 | 13.7% | 0.06 | +11.9% | +13.8% |
| Divi's Laboratories Limited | ₹2.55 L Cr | ₹9,619.5 | 87.0 | 15.21 | 15.3% | 0.00 | +12.3% | +63.1% |
| Torrent Pharmaceuticals Limited | ₹1.90 L Cr | ₹4,928.5 | 79.5 | 22.60 | 25.8% | 1.79 | +21.5% | +36.3% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,889 | 62.5 | 13.48 | 20.5% | 0.90 | +15.7% | +16.6% |
| Lenskart Solutions Limited | ₹1.17 L Cr | ₹680.25 | 177.9 | 13.39 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.17 L Cr | ₹1,180.3 | 26.1 | 4.31 | 18.6% | 0.46 | +18.4% | +13.9% |
| Cipla Limited | ₹1.13 L Cr | ₹1,399.7 | 33.1 | 3.28 | 11.3% | 0.02 | +2.1% | -7.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,007 | 100.4 | 20.52 | 16.8% | 0.48 | +22.0% | +123.9% |
| Mankind Pharma Limited | ₹1.02 L Cr | ₹2,500 | 49.0 | 6.25 | 11.7% | 0.39 | +17.0% | -1.2% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,014 | 70.0 | 9.47 | 13.4% | 0.32 | +19.0% | -10.9% |
| Dr. Reddy's Laboratories Limited | ₹99,991.95 Cr | ₹1,201 | 30.5 | 2.65 | 11.4% | 0.21 | +3.2% | -5.8% |
| Medico Intercontinental Limite | ₹23.60 Cr | ₹23.6 | — | 0.50 | -6.8% | 1.43 | -11.8% | -34.8% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.